We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 459,702 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.90 | 3.10 | 3.00 | 3.00 | 3.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 13.09M | USD -33.29M | USD -0.0320 | -0.94 | 31.25M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:32:07 | O | 18,750 | 3.036 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/2/2025 | 16:30 | ALNC |  Shield Therapeutics shares surge as revenue up on prescription growth |
| 05/2/2025 | 07:00 | UK RNS | Shield Therapeutics PLC Unaudited full year trading update |
| 28/1/2025 | 13:43 | ALNC | EXECUTIVE CHANGES: Smithson changes chairs; British Land taps new COO |
| 27/1/2025 | 07:00 | UK RNS | Shield Therapeutics PLC Anders Lundstrom appointed CEO |
| 24/12/2024 | 11:25 | UK RNS | Shield Therapeutics PLC Result of General Meeting & Total Voting Rights |
| 23/12/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Results of RetailBook Offer |
| 06/12/2024 | 14:35 | ALNC | Shield Therapeutics to raise USD10.0 million via AOP subscription |
| 06/12/2024 | 11:31 | UK RNS | Shield Therapeutics PLC RetailBook Offer |
| 06/12/2024 | 11:30 | UK RNS | Shield Therapeutics PLC Subscription by AOP Health to raise US$10 million |
| 21/11/2024 | 14:22 | ALNC | Shield Therapeutics shares up on strong October sales |
Shield Therapeutics (STX) Share Charts1 Year Shield Therapeutics Chart |
|
1 Month Shield Therapeutics Chart |
Intraday Shield Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/2/2025 | 15:10 | Shield Therapeutics: poised for a US licensing deal | 16,107 |
| 01/11/2024 | 11:41 | Dilution | 1 |
| 30/10/2024 | 12:46 | Dilution | - |
| 09/9/2024 | 14:12 | Shield therapeutics what next? | 1,983 |
| 28/8/2024 | 17:09 | Exceptionally Strong Q2 | 30 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:32:08 | 3.04 | 18,750 | 569.25 | O |
| 09:56:17 | 3.04 | 141,469 | 4,295.00 | O |
| 09:52:10 | 3.02 | 129,059 | 3,895.00 | O |
| 09:32:21 | 3.04 | 1,235 | 37.49 | O |
| 09:30:17 | 3.04 | 658 | 19.98 | O |
| Top Posts |
|---|
Posted at 10/2/2025 08:20 by Shield Therapeutics Daily Update Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 3p.Shield Therapeutics currently has 1,041,690,484 shares in issue. The market capitalisation of Shield Therapeutics is £31,250,715. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.94. This morning STX shares opened at 3p |
Posted at 05/2/2025 15:57 by bolitix The share price will head North in a slightly wacky way as lots will be looking to make small profits. The STX product sales and price will steadily increase though. They said last year they expected revenue to be near $31.5m so surpassed this a little. Hence, no real shocks here. 3 Consecutive fantastic year growth figure will attract others and i see YE25 being a significant 4th year growth reaching 300k+ US sales and in 2026 they will threaten the TVRS $30m trigger payout |
Posted at 19/1/2025 18:11 by razoblade It is understandable, market is skeptical of STX reaching their target so it's waiting for confirmation. Also over a billion shares in issue so it's hard to say where the share price should be currently. It's a waiting game now. |
Posted at 18/1/2025 12:22 by pwhite73 patt - You focus too much on facts and figures that can be easily be demonstrated.Successful investment is not just about facts and figures its also about understanding motives. AOP are stumping up the working capital for STX. They are bearing 100% of the financial risk. Why should they allow you to get rich off their coat tails? There are reasons why the share price is at 2.30p despite AOP injecting another $10 million at 3p. They have incurred a 25% ($2.5 million) loss already. Told you before AOP's interest is in control of the company not the value of the shares. It is my personal belief all are conspiring to take the company private. When done the spoils of the success are shared among the senior executives. I have no idea of your personal finances but I don't believe you can afford another failure like ENET. Be careful. |
Posted at 16/1/2025 11:48 by pwhite73 People are waiting for the Q4 figures due next week. It would be incredulous to think the markets do not already know what these figures are. This may account for the incessant slide in the share price despite AOP paying 3p. Retail shareholders are always the very last to know.I don't believe AOP are concerned with the sales figures at this early stage its control of the company that interests them. They have reasons for taking a 54.53% and its not to do with the current share price either. The Q4 figures may be the catalyst for taking this private. Be careful. |
Posted at 14/1/2025 14:18 by olosnah1 Hargreaves currently selling at 2.30 and also offering to buy my shares at 2.30.The share price is currently down 23% from the recent placing of 3p (or down 42% from the original 4p OAP were going to buy at) Long term holder and a very large (stupidly) holding. I think I am correct that STX end up with a 43% margin from the net sales, taking into account COGS, 5% royalty to Vitra, etc? In which case net income needs to exceed $7.5m a month, of which $3.2m ends up with STX to cover costs/overheads. Or 36k rx per month at average $210. Of course, I may be incorrect, as I was regarding the loan covenant/placing. Whichever way you look, we desperately need an inflection point on the scripts written. My glass half full thinking disappeared a couple of years ago and only hope is some kind of exit near a 8p. |
Posted at 11/12/2024 05:31 by purchaseatthetop “Fort i sold up 6 to 8 weeks ago, it took 2 weeks to get out of holding, no liquidity here, on the upside ended up with a free carry of xxx shares.”Helps explain Pwhites question about who is selling to keep the price down. Not AOP but bored or disillusioned holders who bought very low. “Think BOD are fighting a battle lost against AOP and loan SWP” Loan SWK is within covenants and interest being paid with capital repayments starting Q1 27 when it will be chucking out cash like crazy. Not a problem. AOP are on our side. Without them we would all be screwed. That is clear. “Equity issue was 4p then all changed to 3p - No explanation in RNS’s about change, so a big ?” Why would AOP pay a 40% premium now that the share price drifted from 3.85p to 2.85p? They still pay a 5.3% premium to the market price. Not discounted! Any PI can buy at a better price than that now. I have added four times since mid Nov at 2.85p odd. We have two aces to play: 1) Paediatric indication H1 25 with luck. Suddenly a large number of new pent up demand for under 18s will boost the sales figures accelerating growth. 2) Sallyport invoice factoring. At 30/6/24 the cash received in advance was $6.8m on sales in the quarter of about $7.5m. STX get about 90% of invoice value on issue and then repay when cash collected after 90 days. Then they pay Viatris etc their share. The advance paid balance would have been about the same end Q3 24 as sales only grew marginally. Q4 24 should see US product sales of around 51k at $220 so $11m. That is an extra $3.5m of revenue to get advance cash from. So maybe $3m more. This is the equivalent of obtaining extra funding. So if they get the £1m retail book away, plus this $3m, plus the AOP $10m, they actually have raised nearly $15m. And further sales growth simply increases the Sallyport funding to cash breakeven. |
Posted at 10/12/2024 13:39 by purchaseatthetop 30/10/24 share price was 2.9pSince then we have had the business update saying average prescription revenue has risen to $220 from $167 in Q3 24 (rise of 33%), that 2024 target of $31m will be hit, and AOP have confirmed another $10m cash at 3p. Share price to buy now 2.84p! Well, more for me tomorrow. |
Posted at 08/12/2024 09:45 by pwhite73 patt - "Why should they pay a 35% premium now that the share price has fallen."Because they are the ones who have been shorting the stock down so they get more shares for their $10 million. Where do you think all the 100k, 200k and 300k sells have been coming from keeping the price in the 2.70p - 2.90p range. The closing of the $10 million 3p deal would also include the closing of their short. You see that the share price is down is of no concern to AOP what matters to them is control of the company because once the SWK secured loan is satisfied they will take over STX. When they take over they need offer only the highest price paid in the last twelve months. This is why investors are delusional if they think the share price is going to soar once STX gets paediatric approval, Chinese approval or makes greater traction in the prescribed iron deficiency market. AOP will ensure the share price remains deflated. Given the lack of normal liquidity I doubt STX will see 2025 out as a listed concern. Be careful. |
Posted at 20/11/2024 18:41 by base7 As our share price drifts back towards its lows after yte brief excitement ,my thoughts turn back,again to the previus Proactive when our CEO hinted,in response to my question about Director share buying,that they were previously prohibited but could now buy shares .......yet none of them havent.If they believe in the potential of the company he & Santosh are running, they would surely be buying as many shares as they could afford if they consider our share price to materially understate our prospective value. Those in the know are not buying which emits a very poor signal. |
Posted at 15/11/2024 10:43 by purchaseatthetop “Although there had been some recovery in the share price to ca.5.Op, following the 3Q'24 trading update, the market has become more concerned about the continuing commercial risk and the debate about gross cash. This was exacerbated by the updated view that Shield needed to agree a share subscription for a minimum of $10m from its major shareholder, AOP Health, to get it to cashflow-breakeven. The market needs to see further benefits of the enlarged sales team in each sequential quarter in order to have the confidence to rerate the shares.”Seems accurate enough. Whether the extra risk means the share price should halve when the Rx seems just below $200 now when it was $119 a year ago and prescriptions have doubled in a year! The market seems to be assuming more failures by the new lesdership just like the Madison crew. Maybe not this time. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
